The stock of Silexion Therapeutics Corp (SLXN) has gone up by 16.78% for the week, with a -0.94% drop in the past month and a 23.28% rise in the past quarter. The volatility ratio for the week is 4.35%, and the volatility levels for the past 30 days are 5.12% for SLXN.. The simple moving average for the past 20 days is 12.00% for SLXN’s stock, with a -49.40% simple moving average for the past 200 days.
Is It Worth Investing in Silexion Therapeutics Corp (NASDAQ: SLXN) Right Now?
Company’s 36-month beta value is 0.05.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLXN is 7.91M, and currently, short sellers hold a 3.98% ratio of that floaft. The average trading volume of SLXN on July 09, 2025 was 1.64M shares.
SLXN) stock’s latest price update
Silexion Therapeutics Corp (NASDAQ: SLXN) has experienced a rise in its stock price by 15.67% compared to its previous closing price of $0.81. However, the company has seen a gain of 16.78% in its stock price over the last five trading days. globenewswire.com reported 2025-07-09 that Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204’s Innovative Delivery System; Company is Currently Conducting Additional Studies into New and Previously Untested KRAS Mutation with Results expected in the Near Future Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204’s Innovative Delivery System; Company is Currently Conducting Additional Studies into New and Previously Untested KRAS Mutation with Results expected in the Near Future
SLXN Trading at 2.48% from the 50-Day Moving Average
After a stumble in the market that brought SLXN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.23% of loss for the given period.
Stock Fundamentals for SLXN
The total capital return value is set at -2.19. Equity return is now at value -590.37, with -218.41 for asset returns.
Based on Silexion Therapeutics Corp (SLXN), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -18.6. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is -1179.18.
Currently, EBITDA for the company is -16.43 million with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.22.
Conclusion
In a nutshell, Silexion Therapeutics Corp (SLXN) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
